Companies Werewolf Therapeutics, Inc.
Werewolf Therapeutics (HOWL): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Email me Werewolf Therapeutics, Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $1,366,904FY2023
- $2,545,599FY2024
CEO total pay was $2,545,599 in fiscal 2024, up from $1,366,904 in fiscal 2023.
FY2024: salary $608,237 · bonus $364,638 · stock awards $0 · option awards $1,559,867
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Daniel Hicklin | $608,237 | $364,638 | $0 | $1,559,867 | $0 | $0 | $12,857 | $2,545,599 |
| President and Chief Executive Officer | ||||||||
| Randi Isaacs | 494,145 | 215,843 | 0 | 717,180 | 0 | 0 | 12,857 | 1,440,024 |
| Chief Medical Officer | ||||||||
| Timothy Trost | 465,998 | 199,820 | 0 | 537,885 | 0 | 0 | 12,857 | 1,216,560 |
| Chief Financial Officer and Treasurer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Daniel Hicklin | $2,545,599 | $1,366,904 | — | ↑ +1,178,695 |
| Randi Isaacs | 1,440,024 | 855,765 | — | ↑ +584,259 |
| Timothy Trost | 1,216,560 | 815,585 | — | ↑ +400,975 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company's compensation program is designed to motivate employees to achieve annual goals based on strategic, financial, and operating performance objectives, while equity grants with time-based vesting features are used to promote executive retention and align the interests of executive officers with stockholders.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer & Partners, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Timothy Trost | Option | 4,563 | 16 | — |
| Randi Isaacs | Option | 4,733 | 16 | — |
| Timothy Trost | Option | 10,326 | 5.98 | — |
| Daniel Hicklin | Option | 12,952 | 16 | — |
| Timothy Trost | Option | 17,865 | 11.55 | — |
| Randi Isaacs | Option | 21,536 | 11.55 | — |
| Timothy Trost | Option | 53,542 | 2.05 | — |
| Randi Isaacs | Option | 53,803 | 2.05 | — |
| Daniel Hicklin | Option | 58,470 | 11.55 | — |
| Timothy Trost | Option | 115,625 | 4.64 | — |
| Daniel Hicklin | Option | 153,907 | 2.05 | — |
| Randi Isaacs | Option | 154,167 | 4.64 | — |
| Daniel Hicklin | Option | 335,313 | 4.64 | — |
Director compensation
No director compensation table is on file for fiscal year 2024.
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
Peer group, and who names Werewolf Therapeutics as a peer
Companies that benchmark against HOWL
3 companies name HOWL as a compensation peer
- Astria Therapeutics, Inc.ATXSFY2024
- Mersana Therapeutics, Inc.MRSNFY2024
Each company listed discloses HOWL in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named HOWL in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Werewolf Therapeutics, Inc. | 2024 | Daniel Hicklin | $608,237 | $0 | $1,559,867 | $0 | $2,545,599 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (5 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Daniel Hicklin. DEF 14A, filed 2025-04-28. Section “Executive Compensation”. As printed: 2,545,599. View filing ↗
- Section 01, Randi Isaacs. DEF 14A, filed 2025-04-28. Section “Executive Compensation”. As printed: 1,440,024. View filing ↗
- Section 01, Timothy Trost. DEF 14A, filed 2025-04-28. Section “Executive Compensation”. As printed: 1,216,560. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Werewolf Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Werewolf Therapeutics, Inc.'s own proxy. As printed: 2,545,599. View filing ↗